These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37288716)

  • 41. [Risk factors of clinically significant portal hypertension in patients with compensated liver cirrhosis based on hepatic venous pressure gradient].
    Jiang FR; Yan HD
    Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):995-1000. PubMed ID: 34814395
    [No Abstract]   [Full Text] [Related]  

  • 42. Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update.
    Segna D; Mendoza YP; Lange NF; Rodrigues SG; Berzigotti A
    Dig Liver Dis; 2023 Mar; 55(3):326-335. PubMed ID: 36369196
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Baveno VI criteria as a prognostic factor for clinical complications in patients with compensated cirrhosis.
    Asesio N; Pollo-Flores P; Caliez O; Munteanu M; Ngo A; Ngo Y; Poynard T; Thabut D; Rudler M
    Dig Liver Dis; 2022 May; 54(5):645-653. PubMed ID: 34583904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-invasive diagnosis of esophageal varices after Baveno VI.
    Moctezuma Velázquez C; Abraldes JG
    Turk J Gastroenterol; 2017 May; 28(3):159-165. PubMed ID: 28492370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spleen volume-based non-invasive tool for predicting hepatic decompensation in people with compensated cirrhosis (CHESS1701).
    Yu Q; Xu C; Li Q; Ding Z; Lv Y; Liu C; Huang Y; Zhou J; Huang S; Xia C; Meng X; Lu C; Li Y; Tang T; Wang Y; Song Y; Qi X; Ye J; Ju S
    JHEP Rep; 2022 Nov; 4(11):100575. PubMed ID: 36204707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
    Llop E; Berzigotti A; Reig M; Erice E; Reverter E; Seijo S; Abraldes JG; Bruix J; Bosch J; García-Pagan JC
    J Hepatol; 2012 Jan; 56(1):103-8. PubMed ID: 21827733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Derivation and Validation of a Model to Predict Clinically Significant Portal Hypertension Using Transient Elastography and FIB-4.
    Banini BA; Patel S; Yu JW; Kang L; Bailey C; Strife BJ; Siddiqui MS; Patel V; Matherly SC; Lee H; Lewis S; Cherian R; Stravitz RT; Luketic V; Sanyal AJ; Sterling RK
    J Clin Gastroenterol; 2023 Feb; 57(2):189-197. PubMed ID: 34999644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.
    Berzigotti A; Seijo S; Arena U; Abraldes JG; Vizzutti F; García-Pagán JC; Pinzani M; Bosch J
    Gastroenterology; 2013 Jan; 144(1):102-111.e1. PubMed ID: 23058320
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.
    Petta S; Sebastiani G; Bugianesi E; Viganò M; Wong VW; Berzigotti A; Fracanzani AL; Anstee QM; Marra F; Barbara M; Calvaruso V; Cammà C; Di Marco V; Craxì A; de Ledinghen V
    J Hepatol; 2018 Oct; 69(4):878-885. PubMed ID: 29802949
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
    Podrug K; Trkulja V; Zelenika M; Bokun T; Madir A; Kanizaj TF; O'Beirne J; Grgurevic I
    Dig Dis Sci; 2022 Jul; 67(7):3327-3332. PubMed ID: 34739624
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Moctezuma-Velazquez C; Saffioti F; Tasayco-Huaman S; Casu S; Mason A; Roccarina D; Vargas V; Nilsson JE; Tsochatzis E; Augustin S; Montano-Loza AJ; Berzigotti A; Thorburn D; Genesca J; Abraldes JG
    Am J Gastroenterol; 2019 Mar; 114(3):446-452. PubMed ID: 30315285
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
    Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
    Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extending and validating the Baveno VI criteria for the exclusion of high-risk varices.
    Barbulescu A; Ratiu I; Sporea I; Lungeanu D; Lupusoru R; Miutescu B; Danila M; Popescu A; Sirli R
    Med Ultrason; 2021 Aug; 23(3):265-270. PubMed ID: 33657192
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Noninvasive assessment of the risk of esophageal variceal bleeding from noncirrhotic portal hypertension].
    Xu HF; Wang Y; He FL; Fan ZH; Liu H; Yang YP; Jia JD; Liu FQ; Ding HG
    Zhonghua Gan Zang Bing Za Zhi; 2022 Oct; 30(10):1092-1099. PubMed ID: 36727234
    [No Abstract]   [Full Text] [Related]  

  • 55. Elastography-based screening for esophageal varices in patients with advanced chronic liver disease.
    Paternostro R; Reiberger T; Bucsics T
    World J Gastroenterol; 2019 Jan; 25(3):308-329. PubMed ID: 30686900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease.
    Lee HA; Kim SU; Seo YS; Lee YS; Kang SH; Jung YK; Kim MY; Kim JH; Kim SG; Suk KT; Jung SW; Jang JY; An H; Yim HJ; Um SH
    Liver Int; 2019 Jun; 39(6):1071-1079. PubMed ID: 30589490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices.
    Maurice JB; Brodkin E; Arnold F; Navaratnam A; Paine H; Khawar S; Dhar A; Patch D; O'Beirne J; Mookerjee R; Pinzani M; Tsochatzis E; Westbrook RH
    J Hepatol; 2016 Nov; 65(5):899-905. PubMed ID: 27388923
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
    J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease.
    Mendoza Y; Cocciolillo S; Murgia G; Chen T; Margini C; Sebastiani G; Berzigotti A
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3017-3025.e6. PubMed ID: 32289534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Course of oesophageal varices and performance of noninvasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease.
    Giannini EG; De Maria C; Crespi M; Demarzo MG; Fazio V; Grasso A; Torre F; Bodini G; Marabotto E; Furnari M
    Eur J Clin Invest; 2020 May; 50(5):e13231. PubMed ID: 32291753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.